BioPharma Resources

Drug Trial Radar · NCT07498478

Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment

A Phase II, Open-Label, Multicenter Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of TT-00420 (Tinengotinib) Tablets Combined With Fulvestrant Injection in Patients With Hormone Receptor-Positive (HR+) and Human Epidermal Growth Factor Receptor 2 (HER-2) Negative or Low-Expressing Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment

Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

94

Planned (sponsor's estimate)

Start

Mar 17, 2026

Primary completion

Jun 30, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
First posted
Mar 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if tinengotinib combined with fulvestrant works to treat patients with HR-Positive and HER-2-Negative or low-expressing advanced breast cancer. It will also learn about the safety of combination therapy. The main questions it aims to answer are: 1. Does tinengotinib combined with fulvestrant reduce the tumor burden in participants? 2. What medical problems do participants have when taking the combination therapy? Participants will: Take tinengotinib and fulvestrant to find the optimal dose of tinengotinib for the combination therapy in Part A. In Part B, will take tinengotinib at the optimal dose with fulvestrant or tinengotinib alone to see if the combination therapy works better than tinengotinib monotherapy.

Conditions

  • Breast Cancer

Interventions

  • Tinengotinib at the optimal dose combined with FulvestrantDrug

    Participants will receive tinengotinib at the optimal dose once daily with fulvestrant in 28-day cycles per protocol defined schedule.

  • TinengotinibDrug

    Participants will receive tinengotinib once daily in 28-day cycles per protocol defined schedule.

  • tinengotinib combined with fulvestrantDrug

    Participants will take tinengotinib at the starting dose of 10 mg once daily with fulvestrant to determine the optimal dose of tinengotinib in combination with fulvestrant. If not tolerated, the dose of tinengotinib will be reduced to 8 mg or 6 mg once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: safety evaluation parametersTime frame: From signing of the informed consent until 28 days after the last dose or the end of the study (whichever occurs first), an average of 1 year.
  2. Part B: Objective Response Rate (ORR) (RECIST v1.1)Time frame: From first study drug administration to the end of treatment, an average of 1 year.

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, China · Recruiting

  • Beijing Cancer Hospital

    Beijing, China · Not yet recruiting

  • The First Medical Center, Chinese PLA General Hospital

    Beijing, China · Not yet recruiting

  • Southwest Hospital

    Chongqing, China · Not yet recruiting

  • Fudan University Shanghai Cancer Center

    Shanghai, China · Not yet recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, China · Not yet recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Not yet recruiting

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China · Not yet recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Not yet recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Not yet recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, China · Not yet recruiting

  • Linyi Cancer Hospital

    Linyi, Shandong, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.